JP5159012B2 - 不良溶解性の薬物に対する改良された医薬組成物 - Google Patents

不良溶解性の薬物に対する改良された医薬組成物 Download PDF

Info

Publication number
JP5159012B2
JP5159012B2 JP2001548087A JP2001548087A JP5159012B2 JP 5159012 B2 JP5159012 B2 JP 5159012B2 JP 2001548087 A JP2001548087 A JP 2001548087A JP 2001548087 A JP2001548087 A JP 2001548087A JP 5159012 B2 JP5159012 B2 JP 5159012B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
suspension
drug
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001548087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003518483A (ja
Inventor
ハイエス，デビッド
モレラ，アンジェロ・マリオ
Original Assignee
メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25646230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5159012(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AUPQ4854A external-priority patent/AUPQ485499A0/en
Priority claimed from AUPQ7450A external-priority patent/AUPQ745000A0/en
Application filed by メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド filed Critical メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド
Publication of JP2003518483A publication Critical patent/JP2003518483A/ja
Application granted granted Critical
Publication of JP5159012B2 publication Critical patent/JP5159012B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001548087A 1999-12-23 2000-12-22 不良溶解性の薬物に対する改良された医薬組成物 Expired - Fee Related JP5159012B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU4854 1986-03-03
AUPQ4854A AUPQ485499A0 (en) 1999-12-23 1999-12-23 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ4854 1999-12-23
AU7450 2000-05-12
AUPQ7450A AUPQ745000A0 (en) 2000-05-12 2000-05-12 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ7450 2000-05-12
PCT/AU2000/001592 WO2001047492A1 (en) 1999-12-23 2000-12-22 Improved pharmaceutical compositions for poorly soluble drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012158751A Division JP2012236837A (ja) 1999-12-23 2012-07-17 不良溶解性の薬物に対する改良された医薬組成物

Publications (2)

Publication Number Publication Date
JP2003518483A JP2003518483A (ja) 2003-06-10
JP5159012B2 true JP5159012B2 (ja) 2013-03-06

Family

ID=25646230

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001548087A Expired - Fee Related JP5159012B2 (ja) 1999-12-23 2000-12-22 不良溶解性の薬物に対する改良された医薬組成物
JP2012158751A Pending JP2012236837A (ja) 1999-12-23 2012-07-17 不良溶解性の薬物に対する改良された医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012158751A Pending JP2012236837A (ja) 1999-12-23 2012-07-17 不良溶解性の薬物に対する改良された医薬組成物

Country Status (8)

Country Link
US (3) US20030086976A1 (https=)
EP (2) EP2415462A1 (https=)
JP (2) JP5159012B2 (https=)
AU (2) AU782469B2 (https=)
CA (1) CA2396380C (https=)
ES (1) ES2398643T3 (https=)
PT (1) PT1239831E (https=)
WO (1) WO2001047492A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012236837A (ja) * 1999-12-23 2012-12-06 Mayne Pharma Internatl Pty Ltd 不良溶解性の薬物に対する改良された医薬組成物

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB0012448D0 (en) 2000-05-24 2000-07-12 Astrazeneca Ab New process
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
ZA200905094B (en) * 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
ES2695099T3 (es) * 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
US9650851B2 (en) 2012-06-18 2017-05-16 Schlumberger Technology Corporation Autonomous untethered well object
BR112014031706A8 (pt) * 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
JP2020506905A (ja) * 2017-01-20 2020-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液
US11390613B2 (en) 2017-08-20 2022-07-19 University Of Connecticut Azole analogues and methods of use thereof
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2020159562A1 (en) 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11318107B2 (en) 2019-02-22 2022-05-03 Avior, Inc. Pharmaceutical active-containing film delivery device for oral transmucosal administration
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
PH12022550492A1 (en) * 2019-08-28 2022-12-19 Shenzhen Chipscreen Biosciences Co Ltd Chidamide pharmaceutical composition, preparation method therefor and application thereof
CN115768779A (zh) 2020-05-07 2023-03-07 上海偕怡医药科技有限公司 伊曲康唑前药及其用途
EP4452232A1 (en) * 2021-12-22 2024-10-30 Palau Pharma, S.L.U. Multiparticulate albaconazole composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02167219A (ja) * 1988-12-20 1990-06-27 Fujisawa Pharmaceut Co Ltd 固体分散体の製造方法
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2317106C (en) * 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
JP2002534371A (ja) * 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012236837A (ja) * 1999-12-23 2012-12-06 Mayne Pharma Internatl Pty Ltd 不良溶解性の薬物に対する改良された医薬組成物

Also Published As

Publication number Publication date
CA2396380C (en) 2015-04-21
US20030086976A1 (en) 2003-05-08
AU7252900A (en) 2001-06-28
US20080260835A1 (en) 2008-10-23
EP1239831A1 (en) 2002-09-18
JP2003518483A (ja) 2003-06-10
US8771739B2 (en) 2014-07-08
CA2396380A1 (en) 2001-07-05
AU782469B2 (en) 2005-08-04
US6881745B2 (en) 2005-04-19
EP1239831A4 (en) 2009-07-22
EP2415462A1 (en) 2012-02-08
PT1239831E (pt) 2013-01-23
EP1239831B1 (en) 2012-10-31
WO2001047492A1 (en) 2001-07-05
US20030225104A1 (en) 2003-12-04
AU2331801A (en) 2001-07-09
ES2398643T3 (es) 2013-03-20
JP2012236837A (ja) 2012-12-06

Similar Documents

Publication Publication Date Title
JP5159012B2 (ja) 不良溶解性の薬物に対する改良された医薬組成物
RU2163803C2 (ru) Фармацевтические композиции, содержащие дарифенацин
CA2443089C (en) Antifungal suspension of micronized posaconazole
US20180049974A1 (en) Abuse-resistant formulations
US20040248901A1 (en) Compositions containing itraconazole and their preparation methods
JP2003518485A (ja) 向上された薬物濃度を与える医薬組成物
AU2002257104A1 (en) Antifungal composition with enhanced bioavailability
CA2393737A1 (en) Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption
WO2001089574A1 (en) Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
EP1154762B1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
CN109640948A (zh) 化学组合物
WO2018065952A1 (en) Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
US20060034910A1 (en) Pharmaceutical composition for extended release of phenytoin sodium
EP2808019B1 (en) Improved nitazoxanide composition and preparation method thereof
JP5367570B2 (ja) ロラゼパムの安定化
BR102018016507A2 (pt) Composição líquida de liberação prolongada de guaifenesina
KR101378951B1 (ko) 생체이용률이 향상된 초산 메게스트롤 분말을 포함하는 경구투여용 제제 및 이의 제조방법
Ahmed Formulation and Evaluation of Controlled Release Ketoprofen Microspheres

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120717

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121211

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5159012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151221

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees